Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis

Laboratory Investigation

Volumn 91, Issue 2, 2011, Pages 241-251

  Hennenberg, Martin ^a   Trebicka, Jonel ^a   Kohistani, Zaki ^a   Stark, Christian ^a   Nischalke, Hans Dieter ^a   Krämer, Benjamin ^a   Körner, Christian ^a   Klein, Sabine ^a   Granzow, Michaela ^a   Fischer, Hans Peter ^a   Heller, Jörg ^a   Sauerbruch, Tilman ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

cirrhosis; fibrosis; hepatic stellate cell; portal hypertension; sorafenib

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; PROCOLLAGEN; PROCOLLAGEN 1ALPHA; SORAFENIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BILE DUCT LIGATION; BILIARY CIRRHOSIS; CELL ISOLATION; DNA FRAGMENTATION; DRUG EFFECT; ENZYME ACTIVITY; HISTOPATHOLOGY; IN VITRO STUDY; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ACTINS; ANIMALS; APOPTOSIS; BENZENESULFONATES; CASPASE 3; COLORIMETRY; DNA FRAGMENTATION; HEPATIC STELLATE CELLS; HISTOLOGICAL TECHNIQUES; HYPERTENSION, PORTAL; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS, BILIARY; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS; VASCULAR RESISTANCE;

EID: 79551575060     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.148     Document Type: Article

References (23)

1. Shah V. Therapy for portal hypertension: what is our pipeline? Hepatology 2009;49:4-5.
2. Zhou Q, Hennenberg M, Trebicka J, et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006; 55:1296-1305.
3. Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers in portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007;46: 242-253.
4. Reynaert H, Thompson MG, Thomas T, et al. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002;50:571-581.
5. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-1669.
6. Lee JS, Semela D, Iredale J, et al. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology 2007;45: 817-825.
7. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
8. Hennenberg M, Trebicka J, Stark C, et al. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 2009;157:258-270.
9. Mejias M, Garcia-Pras E, Tiani C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2008;49:1245-1256.
10. Trebicka J, Hennenberg M, Schulze Pröbsting A, et al. Role of beta3- adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology 2009;50:1924-1935.
11. Zhu AX, Clark JW. Commentary: sorafenib use in patients with advanced hepatocellular carcinoma and underlying child-pugh B cirrhosis-evidence and controversy. Oncologist 2009;14:67-69.
12. Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009;14:70-76.
13. Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population. Cancer 2009;115:428-436.
14. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
15. Schramm C, Schuch G, Lohse AW. Sorafenib-induced liver failure. Am J Gastroenterol 2008;103:2162-2163.
16. Llanos L, Bellot P, Zapater P, et al. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib. Am J Gastroenterol 2009;104:257-258.
17. Marra F, DeFranco R, Grappone C, et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 1998; 152:423-430.
18. Kruglov EA, Nathanson RA, Nguyen T, et al. Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts. Am J Physiol Gastrointest Liver Physiol 2006;290: G765-G771.
19. Wörns M.A., Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009 43:489-495.
20. Peck-Radosavljevic M, Greten TF, Lammer J, et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010;22:391-398.
21. Kim S, Yazici YD, Calzada G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007;6:1785-1792.
22. Reiberger T, Angermayr B, Schwabl R, et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 2009;51:865-873.
23. Tugues S, Fernandez-Varo G, Munoz-Luque J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007;46:1919-1926.